Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.78 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.63 |
| ▸ | FAP | Q12884 | 2/20 | 0.63 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.63 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7021069 | 1.00 | DPP4 (0.78) | DPP4DPP8FAPDPP9DPP7 | |
| SCHEMBL7403443 | 1.00 | DPP4 (0.78) | DPP4DPP8FAPDPP9DPP7 | |
| SCHEMBL19743784 | 1.00 | DPP4 (0.78) | DPP4DPP8FAPDPP9DPP7 | |
| SCHEMBL6238520 | 0.87 | DPP4 (1.00) | DPP4DPP8FAPDPP9DPP7 | |
| SCHEMBL5647935 | 0.87 | DPP4 (1.00) | DPP4DPP8FAPDPP9DPP7 | |
| SCHEMBL5647937 | 0.87 | DPP4 (1.00) | DPP4DPP8FAPDPP9DPP7 | |
| SCHEMBL6238524 | 0.87 | DPP4 (1.00) | DPP4DPP8FAPDPP9DPP7 | |
| Hydrochloric Acid SCHEMBL3601691 | 0.86 | DPP4 (0.97) | DPP4DPP8FAPDPP9DPP7 | |
| Hydrochloric Acid SCHEMBL5652234 | 0.86 | DPP4 (0.97) | DPP4DPP8FAPDPP9DPP7 | |
| Hydrochloric Acid SCHEMBL5652236 | 0.86 | DPP4 (0.97) | DPP4DPP8FAPDPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6468977-B1 | COMPOUNDS USEFUL IN TREATMENT TREATMENT OF DISORDER AND/OR DISEASE CAUSED BY ACTIVITY OF ENZYMES SUCH AS HUMAN RHINOVIRUS 3C PROTEASE, TRANSGLUTAMINASE AND CATHEPSINS | APOTEX INC. (CA) | 2002-10-22 | — | — | US | claimed |
| WO-2001090095-A1 | THIADIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF CYSTEINE ACTIVITY DEPENDENT ENZYMES | APOTEX INC. (CA) | 2001-11-29 | — | — | WO | claimed |
| CN-1291993-A | Thiadiazole compounds useful as cysteine activity dependent enzyme inhibitors | APOTEX INC (CA) | 2001-04-18 | — | — | CN | claimed |
| US-6162791-A | Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes | APOTEX INC. (CA) | 2000-12-19 | — | — | US | claimed |
| EP-1058690-A1 | THIADIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF CYSTEINE ACTIVITY DEPENDENT ENZYMES | APOTEX INC. (CA) | 2000-12-13 | — | — | EP | claimed |
| WO-1999045027-A1 | THIADIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF CYSTEINE ACTIVITY DEPENDENT ENZYMES | APOTEX INC. (CA) | 1999-09-10 | — | — | WO | claimed |
| EP-3897637-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | Novartis AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020128972-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| EP-3472176-A1 | UTILITY OF (+) EPICATECHIN AND THEIR ANALOGS | Sphaera Pharma Pvt. Ltd. (IN) | 2019-04-24 | — | — | EP | disclosed |
| EP-3472161-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017221092-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2017-12-28 | — | — | WO | disclosed |
| WO-2017221269-A1 | UTILITY OF (+) EPICATECHIN AND THEIR ANALOGS | SPHAERA PHARMA PVT. LTD., (IN) | 2017-12-28 | — | — | WO | disclosed |
| US-8680263-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2014-03-25 | — | — | US | disclosed |
| US-6468977-B1 | COMPOUNDS USEFUL IN TREATMENT TREATMENT OF DISORDER AND/OR DISEASE CAUSED BY ACTIVITY OF ENZYMES SUCH AS HUMAN RHINOVIRUS 3C PROTEASE, TRANSGLUTAMINASE AND CATHEPSINS | APOTEX INC. (CA) | 2002-10-22 | — | — | US | disclosed |
| WO-2001090095-A1 | THIADIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF CYSTEINE ACTIVITY DEPENDENT ENZYMES | APOTEX INC. (CA) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001081321-A1 | METHOD FOR PRODUCING 2,5-DIKETOPIPERAZINES, 2,5-DIKETOPIPERAZINES, DIPEPTIDES AND THE USE THEREOF | DEGUSSA AG (DE) | 2001-11-01 | — | — | WO | disclosed |
| CN-1291993-A | Thiadiazole compounds useful as cysteine activity dependent enzyme inhibitors | APOTEX INC (CA) | 2001-04-18 | — | — | CN | disclosed |
| US-6162791-A | Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes | APOTEX INC. (CA) | 2000-12-19 | — | — | US | disclosed |
| EP-1058690-A1 | THIADIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF CYSTEINE ACTIVITY DEPENDENT ENZYMES | APOTEX INC. (CA) | 2000-12-13 | — | — | EP | disclosed |
| WO-1999045027-A1 | THIADIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF CYSTEINE ACTIVITY DEPENDENT ENZYMES | APOTEX INC. (CA) | 1999-09-10 | — | — | WO | disclosed |